# Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

> **NCT01453998** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 657 (actual)

## Conditions studied

- Acellular Pertussis
- Hepatitis B
- Haemophilus Influenzae Type b
- Tetanus
- Diphtheria
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Infanrix hexa
- **BIOLOGICAL:** Prevenar 13
- **BIOLOGICAL:** GSK217744

## Key facts

- **NCT ID:** NCT01453998
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-14
- **Primary completion:** 2012-11-12
- **Final completion:** 2012-11-12
- **Target enrollment:** 657 (ACTUAL)
- **Last updated:** 2020-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453998, "Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01453998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*